1-9 of 9
Mark M. Moasser
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Molecular Pathways and Mechanisms of HER2 in Cancer Therapy

Available to Purchase
Kanwal P.S. Raghav, Mark M. Moasser
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (13): 2351–2361.
https://doi.org/10.1158/1078-0432.CCR-22-0283
Published: 05 July 2023
View articletitled, Molecular Pathways and Mechanisms of HER2 in Cancer Therapy
Open the PDF for Molecular Pathways and Mechanisms of HER2 in Cancer Therapy in another window
Journal Articles

HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive

Free
Marcia R. Campbell, Mark M. Moasser
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (13): 2886–2888.
https://doi.org/10.1158/1078-0432.CCR-14-3012
Published: 30 June 2015
View articletitled, HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive
Open the PDF for HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive in another window
Journal Articles

HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy

Free
Marcia R. Campbell, Dhara Amin, Mark M. Moasser
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (5): 1373–1383.
https://doi.org/10.1158/1078-0432.CCR-09-1218
Published: 28 February 2010
View articletitled, HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy
Open the PDF for HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy in another window
Journal Articles

A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies

Free
Amy J. Chien, Julie A. Illi, Andrew H. Ko, Wolfgang M. Korn, Lawrence Fong, Lee-may Chen, Mohammed Kashani-Sabet, Charles J. Ryan, Jonathan E. Rosenberg, Sarita Dubey, Eric J. Small, Thierry M. Jahan, Nola M. Hylton, Benjamin M. Yeh, Yong Huang, Kevin M. Koch, Mark M. Moasser
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (17): 5569–5575.
https://doi.org/10.1158/1078-0432.CCR-09-0522
Published: 31 August 2009
View articletitled, A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies
Open the PDF for A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies in another window
Journal Articles

Phosphorylation of the src Epithelial Substrate Trask Is Tightly Regulated in Normal Epithelia but Widespread in Many Human Epithelial Cancers

Free
Ching Hang Wong, Frederick L. Baehner, Danislav S. Spassov, Deepika Ahuja, Donghui Wang, Byron Hann, Jimmy Blair, Kevan Shokat, Alana L. Welm, Mark M. Moasser
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (7): 2311–2322.
https://doi.org/10.1158/1078-0432.CCR-08-2533
Published: 01 April 2009
View articletitled, Phosphorylation of the src Epithelial Substrate Trask Is Tightly Regulated in Normal Epithelia but Widespread in Many Human Epithelial Cancers
Open the PDF for Phosphorylation of the src Epithelial Substrate Trask Is Tightly Regulated in Normal Epithelia but Widespread in Many Human Epithelial Cancers in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer

Free
Maura N. Dickler, Hope S. Rugo, Carey A. Eberle, Edi Brogi, James F. Caravelli, Katherine S. Panageas, Jeff Boyd, Benjamin Yeh, Diana E. Lake, Chau T. Dang, Teresa A. Gilewski, Jacqueline F. Bromberg, Andrew D. Seidman, Gabriella M. D'Andrea, Mark M. Moasser, Michele Melisko, John W. Park, Janet Dancey, Larry Norton, Clifford A. Hudis
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (23): 7878–7883.
https://doi.org/10.1158/1078-0432.CCR-08-0141
Published: 01 December 2008
View articletitled, A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer
Open the PDF for A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments

Free
Chau T. Dang, Andrew J. Dannenberg, Kotha Subbaramaiah, Maura N. Dickler, Mark M. Moasser, Andrew D. Seidman, Gabriella M. D’Andrea, Maria Theodoulou, Katherine S. Panageas, Larry Norton, Clifford A. Hudis
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (12): 4062–4067.
https://doi.org/10.1158/1078-0432.CCR-03-0463
Published: 24 June 2004
View articletitled, Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments
Open the PDF for Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments in another window
Journal Articles

Resistance to Gefitinib in PTEN-Null HER-Overexpressing Tumor Cells Can Be Overcome through Restoration of PTEN Function or Pharmacologic Modulation of Constitutive Phosphatidylinositol 3′-Kinase/Akt Pathway Signaling

Free
Qing-Bai She, David Solit, Andrea Basso, Mark M. Moasser
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (12): 4340–4346.
Published: 10 October 2003
View articletitled, Resistance to Gefitinib in PTEN-Null HER-Overexpressing Tumor Cells Can Be Overcome through Restoration of PTEN Function or Pharmacologic Modulation of Constitutive Phosphatidylinositol 3′-Kinase/Akt Pathway Signaling
Open the PDF for Resistance to Gefitinib in PTEN-Null HER-Overexpressing Tumor Cells Can Be Overcome through Restoration of PTEN Function or Pharmacologic Modulation of Constitutive Phosphatidylinositol 3′-Kinase/Akt Pathway Signaling in another window
Journal Articles

A Novel Pyridopyrimidine Inhibitor of Abl Kinase Is a Picomolar Inhibitor of Bcr-abl-driven K562 Cells and Is Effective against STI571-resistant Bcr-abl Mutants

Free
David R. Huron, Mercedes E. Gorre, Alan J. Kraker, Charles L. Sawyers, Neal Rosen, Mark M. Moasser
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (4): 1267–1273.
Published: 01 April 2003
View articletitled, A Novel Pyridopyrimidine Inhibitor of Abl Kinase Is a Picomolar Inhibitor of Bcr-abl-driven K562 Cells and Is Effective against STI571-resistant Bcr-abl Mutants
Open the PDF for A Novel Pyridopyrimidine Inhibitor of Abl Kinase Is a Picomolar Inhibitor of Bcr-abl-driven K562 Cells and Is Effective against STI571-resistant Bcr-abl Mutants in another window